CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

The National Thoroughbred Racing Association (NTRA), Daily Racing Form, and the National Turf Writers and Broadcasters (NTWAB) have announced that Frank Taylor and the Stable Recovery Program will be ...

Heather Eracleous is no stranger to recycling projects. She is the owner of Vessel Refillery FW, where residents of Fort Wayne, Indiana, can refill their empty bottles of household goods and personal ...